156 related articles for article (PubMed ID: 35726954)
21. MAGIC-DR: An interpretable machine-learning guided approach for acute myeloid leukemia measurable residual disease analysis.
Shopsowitz K; Lofroth J; Chan G; Kim J; Rana M; Brinkman R; Weng A; Medvedev N; Wang X
Cytometry B Clin Cytom; 2024 Feb; ():. PubMed ID: 38415807
[TBL] [Abstract][Full Text] [Related]
22. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
23. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
[TBL] [Abstract][Full Text] [Related]
24. The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia.
Wang XY; Fan QZ; Xu LP; Wang Y; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Liu YR; Mo XD; Liu KY; Huang XJ; Chang YJ
Cytometry B Clin Cytom; 2020 Jan; 98(1):75-87. PubMed ID: 31424628
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
[TBL] [Abstract][Full Text] [Related]
26. Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data.
Fišer K; Sieger T; Schumich A; Wood B; Irving J; Mejstříková E; Dworzak MN
Cytometry A; 2012 Jan; 81(1):25-34. PubMed ID: 21990127
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
[TBL] [Abstract][Full Text] [Related]
28. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
[TBL] [Abstract][Full Text] [Related]
29. A Single-Tube 21-Color Multiparameter Flow Cytometry Improve the Sensitivity of B-ALL MRD Analysis.
Wang Q; You R; Miao L; Lu Y; Gong Y; Wu X; Ge H; Zhai S; Qu C
Clin Lab; 2023 Sep; 69(9):. PubMed ID: 37702686
[TBL] [Abstract][Full Text] [Related]
30. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
[TBL] [Abstract][Full Text] [Related]
31. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
32. Measurable residual disease in adult acute myeloid leukaemia: evaluation of a multidimensional 'radar' flow cytometric plot analysis method.
van der Linde R; Smith S; Brown DA; Sasson SC; Tegg E
Pathology; 2023 Apr; 55(3):383-390. PubMed ID: 36725446
[TBL] [Abstract][Full Text] [Related]
33. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
[TBL] [Abstract][Full Text] [Related]
34. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
35. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
[TBL] [Abstract][Full Text] [Related]
36. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry.
Farahat N; Morilla A; Owusu-Ankomah K; Morilla R; Pinkerton CR; Treleaven JG; Matutes E; Powles RL; Catovsky D
Br J Haematol; 1998 Apr; 101(1):158-64. PubMed ID: 9576196
[TBL] [Abstract][Full Text] [Related]
37. Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey.
Hupp MM; Bashleben C; Cardinali JL; Dorfman DM; Karlon W; Keeney M; Leith C; Long T; Murphy CE; Pillai V; Rosado FN; Seegmiller AC; Linden MA
Arch Pathol Lab Med; 2021 Mar; 145(3):336-342. PubMed ID: 32886757
[TBL] [Abstract][Full Text] [Related]
38. Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(8):1-83. PubMed ID: 27099644
[TBL] [Abstract][Full Text] [Related]
39. 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL.
Goshaw JM; Gao Q; Wardrope J; Dogan A; Roshal M
Cytometry B Clin Cytom; 2021 Jul; 100(4):509-518. PubMed ID: 32896973
[TBL] [Abstract][Full Text] [Related]
40. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
